| Hypertension in the elderly and the very old. | |
| | |
MedLine Citation:
|
PMID: 19505281 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
High systolic blood pressure represents a challenge for the modern world. Epidemiologists are in the best position to appreciate the importance of systolic hypertension and its cardiovascular consequences. Although the label of hypertension seems to have lower importance in the elderly, and above all in the very old, than in younger people, high systolic and high pulse pressure are risk factors for cardiovascular events and necessitates treatment. Unfortunately, due to indolence and lack of aggressiveness, only a limited fraction of elderly hypertensive patients receives adequate therapy. |
| | |
Authors:
|
Edoardo Casiglia; Valérie Tikhonoff; Achille C Pessina |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert review of cardiovascular therapy Volume: 7 ISSN: 1744-8344 ISO Abbreviation: Expert Rev Cardiovasc Ther Publication Date: 2009 Jun |
Date Detail:
|
Created Date: 2009-06-09 Completed Date: 2009-08-17 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101182328 Medline TA: Expert Rev Cardiovasc Ther Country: England |
Other Details:
|
Languages: eng Pagination: 659-65 Citation Subset: IM |
Affiliation:
|
Department of Clinical & Experimental Medicine, University of Padova, Via Giustiniani No. 2, Padova I-35128, Italy. edoardo.casiglia@unipd.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Age Factors Aged Aged, 80 and over Antihypertensive Agents / therapeutic use Blood Pressure / drug effects* Cardiovascular Diseases / etiology*, physiopathology Humans Hypertension / complications, drug therapy*, physiopathology Risk Factors |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Concepts guiding therapy for hypertension in children.
Next Document: Blocking the renin-angiotensin system: dual- versus mono-therapy.